Per- and Polyfluoroalkyl Substances (PFAS) and Lipid Trajectories in Women 45-56 Years of Age: The Study of Women's Health Across the Nation.


Journal

Environmental health perspectives
ISSN: 1552-9924
Titre abrégé: Environ Health Perspect
Pays: United States
ID NLM: 0330411

Informations de publication

Date de publication:
08 2023
Historique:
medline: 9 8 2023
pubmed: 8 8 2023
entrez: 8 8 2023
Statut: ppublish

Résumé

Per- and polyfluoroalkyl substances (PFAS) are associated with less favorable blood lipid profiles in epidemiological studies. However, little is known about the potential role of PFAS in longitudinal changes in lipids among midlife women even though women become more susceptible to metabolic alterations during the menopausal transition. To examine associations of serum PFAS concentrations with longitudinal trajectories of blood total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides in midlife women undergoing menopausal transition. The sample included 1,130 women from the Study of Women's Health Across the Nation 45-56 y of age at baseline (1999-2000). We measured serum PFAS concentrations including linear perfluorooctanoic acid (n-PFOA), perfluorononanoic acid (PFNA), linear and branched perfluorooctanesulfonic acid (n-PFOS and Sm-PFOS, respectively), and perfluorohexanesulfonic acid (PFHxS) at baseline. We used Three distinct trajectories (low, middle, high) of total, LDL, and HDL cholesterol and two distinct trajectories (low and high) of triglycerides were identified. n-PFOS, Sm-PFOS, and PFHxS were positively associated with total and LDL cholesterol trajectories. n-PFOS was inversely associated with triglycerides trajectories. PFAS mixtures (high vs. low) showed positive associations with total and LDL cholesterol trajectories (high vs. low), showing ORs (95% CIs) of 1.69 (95% CI: 1.36, 2.12) and 1.79 (95% CI: 1.44, 2.22), respectively. Concentrations of serum PFAS were positively associated with trajectories of total and LDL cholesterol, providing a line of evidence supporting adverse effects of PFAS on lipid homeostasis. https://doi.org/10.1289/EHP12351.

Sections du résumé

BACKGROUND
Per- and polyfluoroalkyl substances (PFAS) are associated with less favorable blood lipid profiles in epidemiological studies. However, little is known about the potential role of PFAS in longitudinal changes in lipids among midlife women even though women become more susceptible to metabolic alterations during the menopausal transition.
OBJECTIVES
To examine associations of serum PFAS concentrations with longitudinal trajectories of blood total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides in midlife women undergoing menopausal transition.
METHODS
The sample included 1,130 women from the Study of Women's Health Across the Nation 45-56 y of age at baseline (1999-2000). We measured serum PFAS concentrations including linear perfluorooctanoic acid (n-PFOA), perfluorononanoic acid (PFNA), linear and branched perfluorooctanesulfonic acid (n-PFOS and Sm-PFOS, respectively), and perfluorohexanesulfonic acid (PFHxS) at baseline. We used
RESULTS
Three distinct trajectories (low, middle, high) of total, LDL, and HDL cholesterol and two distinct trajectories (low and high) of triglycerides were identified. n-PFOS, Sm-PFOS, and PFHxS were positively associated with total and LDL cholesterol trajectories. n-PFOS was inversely associated with triglycerides trajectories. PFAS mixtures (high vs. low) showed positive associations with total and LDL cholesterol trajectories (high vs. low), showing ORs (95% CIs) of 1.69 (95% CI: 1.36, 2.12) and 1.79 (95% CI: 1.44, 2.22), respectively.
DISCUSSION
Concentrations of serum PFAS were positively associated with trajectories of total and LDL cholesterol, providing a line of evidence supporting adverse effects of PFAS on lipid homeostasis. https://doi.org/10.1289/EHP12351.

Identifiants

pubmed: 37552133
doi: 10.1289/EHP12351
pmc: PMC10408595
doi:

Substances chimiques

Cholesterol, LDL 0
Environmental Pollutants 0
Alkanesulfonic Acids 0
perfluorohexanesulfonic acid 355-46-4
Lipids 0
Fluorocarbons 0
Cholesterol 97C5T2UQ7J
Triglycerides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

87004

Subventions

Organisme : NIA NIH HHS
ID : U01 AG012554
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG024824
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : ACL HHS
ID : T42OH008455
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES017885
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012505
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK092926
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES035087
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012535
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012553
Pays : United States
Organisme : NINR NIH HHS
ID : U01 NR004061
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012539
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES026578
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012546
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG063720
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012495
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG012531
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES026964
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG017719
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Chromatogr A. 2011 Apr 15;1218(15):2133-7
pubmed: 21084089
Toxics. 2020 Dec 20;8(4):
pubmed: 33419269
PLoS One. 2013 Apr 23;8(4):e61409
pubmed: 23626681
Environ Res. 2022 Mar;204(Pt B):112111
pubmed: 34563522
Environ Res. 2022 Aug;211:112903
pubmed: 35231461
J Lipid Res. 2002 Mar;43(3):383-91
pubmed: 11893774
Environ Health Perspect. 2022 Apr;130(4):46001
pubmed: 35475652
Environ Pollut. 2021 Jun 15;279:116929
pubmed: 33751946
Toxicology. 2022 Jan 15;465:153044
pubmed: 34800597
Prev Med. 1999 Mar;28(3):313-23
pubmed: 10072751
Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1800-5
pubmed: 9327780
Environ Health Perspect. 2017 Mar;125(3):416-421
pubmed: 27529882
J Pharmacol Exp Ther. 1998 Jul;286(1):561-8
pubmed: 9655903
Epidemiology. 2013 Jul;24(4):569-76
pubmed: 23685825
Arch Toxicol. 2012 Jan;86(1):63-74
pubmed: 21499893
Environ Int. 2019 Mar;124:58-65
pubmed: 30639908
Mol Cell Endocrinol. 2015 Jan 15;400:90-101
pubmed: 25448844
J Endocrinol. 2012 Jan;212(1):3-12
pubmed: 21511884
Int J Mol Med. 2014 Mar;33(3):550-8
pubmed: 24398697
Environ Int. 2021 Oct;155:106596
pubmed: 33940391
Environ Int. 2019 Aug;129:343-353
pubmed: 31150976
Int J Environ Res Public Health. 2018 May 14;15(5):
pubmed: 29758015
Toxicol Appl Pharmacol. 2020 Oct 15;405:115204
pubmed: 32822737
Environ Res. 2019 Aug;175:186-199
pubmed: 31129528
Am J Epidemiol. 1986 Sep;124(3):453-69
pubmed: 3740045
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Gynecol Endocrinol. 2011 Sep;27(9):701-5
pubmed: 20807164
Med Sci Sports Exerc. 2000 Jul;32(7):1327-38
pubmed: 10912901
Environ Sci Technol. 2014;48(15):8807-14
pubmed: 24943117
Eur J Epidemiol. 2016 Jun;31(6):583-92
pubmed: 26955830
PLoS One. 2013;8(2):e56969
pubmed: 23441227
Environ Int. 2020 Dec;145:106117
pubmed: 32971418
Environ Pollut. 2018 Jan;232:73-79
pubmed: 28923343
Environ Res. 2013 Feb;121:95-103
pubmed: 23266098
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4427-e4437
pubmed: 34181018
J Am Coll Cardiol. 2009 Dec 15;54(25):2366-73
pubmed: 20082925
Environ Int. 2020 Dec;145:106125
pubmed: 32950793
Hum Reprod Update. 2020 Sep 1;26(5):724-752
pubmed: 32476019
Am J Epidemiol. 2009 Nov 15;170(10):1268-78
pubmed: 19846564
Crit Rev Toxicol. 2021 Feb;51(2):141-164
pubmed: 33853480
Toxicol Rep. 2016;3:46-54
pubmed: 26942110
J Occup Environ Med. 2007 Aug;49(8):872-9
pubmed: 17693785
Maturitas. 2021 Apr;146:49-56
pubmed: 33722364
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32491182
Environ Sci Technol. 2012 Sep 4;46(17):9274-81
pubmed: 22862179
Environ Int. 2020 Feb;135:105381
pubmed: 31841808
Toxicology. 2021 Jul;459:152845
pubmed: 34246716
Environ Res. 2015 Nov;143(Pt A):33-8
pubmed: 26432473
Toxicology. 2011 Oct 9;288(1-3):8-17
pubmed: 21723365
Environ Health Perspect. 2014 Dec;122(12):1299-305
pubmed: 25260175
J Clin Endocrinol Metab. 2012 Aug;97(8):2872-80
pubmed: 22659249
Environ Toxicol Chem. 2014 Sep;33(9):1921-9
pubmed: 24924660
Stat Med. 2005 Oct 15;24(19):2911-35
pubmed: 16152135
BMC Genet. 2007 Sep 10;8:60
pubmed: 17845730
Environ Sci Technol. 2022 May 3;56(9):5664-5672
pubmed: 35438966
Chemosphere. 2016 Jul;155:436-443
pubmed: 27139122
Int J Obes (Lond). 2021 Sep;45(9):1937-1948
pubmed: 33986457
PLoS One. 2016 Jul 21;11(7):e0159550
pubmed: 27442011
Environ Health Perspect. 2022 Jun;130(6):67007
pubmed: 35731224
J Occup Environ Med. 2003 Mar;45(3):260-70
pubmed: 12661183
Toxicology. 2017 Mar 01;378:37-52
pubmed: 28049043
Environ Res. 2010 Oct;110(7):710-7
pubmed: 20696425

Auteurs

Habyeong Kang (H)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Institute of Health Sciences, College of Health Science, Korea University, Seoul, Republic of Korea.

Ning Ding (N)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Carrie A Karvonen-Gutierrez (CA)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Bhramar Mukherjee (B)

Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Antonia M Calafat (AM)

Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sung Kyun Park (SK)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH